MM Regan
About
MM Regan is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Genetics.
According to data from OpenAlex, MM Regan has authored 32 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cancer Research, 19 papers in Pulmonary and Respiratory Medicine and 18 papers in Genetics. Recurrent topics in MM Regan's work include Breast Cancer Treatment Studies (22 papers), Advanced Breast Cancer Therapies (17 papers) and Estrogen and related hormone effects (17 papers). MM Regan is often cited by papers focused on Breast Cancer Treatment Studies (22 papers), Advanced Breast Cancer Therapies (17 papers) and Estrogen and related hormone effects (17 papers). MM Regan collaborates with scholars based in Switzerland, United States and Belgium. MM Regan's co-authors include Mathew J. Ellis, Torsten O. Nielsen, Tracy Lively, Janine Salter, Seungmok Paik, Christos Sotiriou, Daniel F. Hayes, N. Lynn Henry, Judith Hugh and J Cuzick and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.
In The Last Decade
MM Regan
29 papers receiving 1.7k citations
Hit Papers
Peers
MM Regan
J. Zujewski United States
Tracey Weisberg United States
Leticia Varella United States
Elizabeth Mallon United Kingdom
Rie Horii Japan
Sean Ferree United States
Wanseop Kim United States
Dalia M. Abd El‐Rehim Egypt
Friedrich Otterbach Germany
P. Kelly Marcom United States
Citations per year, relative to MM Regan MM Regan (= 1×)
peers
J. Zujewski
Countries citing papers authored by MM Regan
Since
Specialization
Citations
This map shows the geographic impact of MM Regan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MM Regan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MM Regan more than expected).
Fields of papers citing papers by MM Regan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by MM Regan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MM Regan. The network helps show where MM Regan may publish in the future.
Co-authorship network of co-authors of MM Regan
This figure shows the co-authorship network connecting the top 25 collaborators of MM Regan. A scholar is included among the top collaborators of MM Regan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with MM Regan. MM Regan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bellet, Meritxell, Prudence A. Francis, István Láng, et al.. (2019). Abstract P4-14-01: Estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis. Cancer Research. 79(4_Supplement). P4–14.
2.
Láng, István, Eva Ciruelos, Meritxell Bellet, et al.. (2018). Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial. Cancer Research. 78(4_Supplement). GS4–3.
3.
Loi, Shrushma, Andrea Gombos, Rina Hui, et al.. (2018). Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study. Cancer Research. 78(4_Supplement). GS2–6.
4.
Ribi, Karin, Wenjie Luo, Marco Colleoni, et al.. (2018). Abstract P5-18-01: Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-07 SOLE): Impact on patient-reported symptoms and quality of life. Cancer Research. 78(4_Supplement). P5–18.
5.
Loi, Shrushma, Anita Giobbie‐Hurder, Andrea Gombos, et al.. (2017). Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014). Open Repository and Bibliography (University of Liège).
6.
Gennari, Alessandra, Marco Colleoni, John F. Kennedy, et al.. (2017). Abstract P5-15-05: Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study. Cancer Research. 77(4_Supplement). P5–15.
7.
Regan, MM, Olivia Pagani, K.N. Price, et al.. (2017). Abstract OT3-02-03: Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer. Cancer Research. 77(4_Supplement). OT3–2.
8.
Overmoyer, Beth, MM Regan, Craig A. Bunnell, et al.. (2017). Abstract P6-12-12: Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC). Cancer Research. 77(4_Supplement). P6–12.
9.
Borgquist, Signe, Anita Giobbie‐Hurder, Thomas P. Ahern, et al.. (2016). Abstract PD1-03: Cholesterol, cholesterol lowering medication use, and breast cancer outcomes in the BIG 1-98 study. Cancer Research. 76(4_Supplement). PD1–3.
10.
Pruneri, Giancarlo, Andrea Vingiani, Giuseppe Viale, et al.. (2016). Abstract P2-08-02: Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer treated by induction chemotherapy with or without oral low dose cyclophosphamide-methotrexate maintenance chemotherapy (CMM). Cancer Research. 76(4_Supplement). P2–8.
11.
Regan, MM, U. Dafni, Dimitris Karlis, et al.. (2012). Abstract P5-18-02: Selective Crossover in Randomized Trials of Adjuvant Trastuzumab for Breast Cancer: Coping with Success. Cancer Research. 72(24_Supplement). P5–18.
12.
Sotiriou, Christos, Michail Ignatiadis, Christine Desmedt, et al.. (2012). Abstract S4-4: Independent validation of Genomic Grade in the BIG 1-98 study. Cancer Research. 72(24_Supplement). S4–4.
13.
Viale, Giuseppe, MM Regan, Patrizia Dell’Orto, et al.. (2011). Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of Oncology. 22(10). 2201–2207.
14.
Nielsen, Torsten O., Roger A’Hern, R. Charles Coombes, et al.. (2011). Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. JNCI Journal of the National Cancer Institute. 103(22). 1656–1664.
15.
Gelber, RD, Anita Giobbie‐Hurder, L. Mauriac, et al.. (2011). 5016 POSTER DISCUSSION BIG 1-98 Update: Evaluating Letrozole and Tamoxifen Alone and in Sequence at 8 Years Median Follow-up for Postmenopausal Women With Steroid Hormone Receptor-Positive Breast Cancer. European Journal of Cancer. 47. S334–S335.
16.
Leyland-Jones, B, MM Regan, Mark Bouzyk, et al.. (2010). Abstract S1-8: Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial. Cancer Research. 70(24_Supplement). S1–8.
17.
Viale, Giuseppe, MM Regan, Patrizia Dell’Orto, et al.. (2009). Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.. Cancer Research. 69(24_Supplement). 76–76.
18.
Regan, MM, Marco Colleoni, Anita Giobbie‐Hurder, et al.. (2009). Adjusting for Selective Crossover in Analyses of Letrozole (Let) Versus Tamoxifen (Tam) in the BIG 1-98 Trial.. Cancer Research. 69(24_Supplement). 16–16.
19.
Giobbie‐Hurder, Anita, MM Regan, Patrizia Dell’Orto, et al.. (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole. Journal of Clinical Oncology. 26. 5569–5575.
20.
Rasmussen, Blake B., MM Regan, Patrizia Dell’Orto, et al.. (2007). Central assessment of ER, PgR and HER2 in BIG 1–98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. Journal of Clinical Oncology. 25(18_suppl). 538–538.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by J. Zujewski Breakdown of academic impact, for papers by Tracey Weisberg Breakdown of academic impact, for papers by Leticia Varella Breakdown of academic impact, for papers by Elizabeth Mallon Breakdown of academic impact, for papers by Rie Horii Breakdown of academic impact, for papers by Sean Ferree Breakdown of academic impact, for papers by Wanseop Kim Breakdown of academic impact, for papers by Dalia M. Abd El‐Rehim Breakdown of academic impact, for papers by Friedrich Otterbach Breakdown of academic impact, for papers by P. Kelly Marcom